Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2015, Article ID 629382, 13 pages
http://dx.doi.org/10.1155/2015/629382
Review Article

Evidence-Based Treatments for Adults with Migraine

Department of Neurology, Hull Royal Infirmary, Hull, UK

Received 17 October 2015; Accepted 9 December 2015

Academic Editor: Hartmut Göbel

Copyright © 2015 Rubesh Gooriah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. J. Steiner, A. I. Scher, W. F. Stewart, K. Kolodner, J. Liberman, and R. B. Lipton, “The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity,” Cephalalgia, vol. 23, no. 7, pp. 519–527, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. T. J. Steiner, L. J. Stovner, and G. L. Birbeck, “Migraine: the seventh disabler,” The Journal of Headache and Pain, vol. 14, article 1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Natoli, A. Manack, B. Dean et al., “Global prevalence of chronic migraine: a systematic review,” Cephalalgia, vol. 30, no. 5, pp. 599–609, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Bigal, “The paradoxical effects of analgesics and the development of chronic migraine,” Arquivos de Neuro-Psiquiatria, vol. 69, no. 3, pp. 544–551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. IHS, “The international classification of headache disorders, 3rd edition (beta version),” Cephalalgia, vol. 33, no. 33, pp. 629–808, 2013. View at Publisher · View at Google Scholar
  6. C. E. Clarke, L. MacMillan, S. Sondhi, and N. E. J. Wells, “Economic and social impact of migraine,” QJM—Monthly Journal of the Association of Physicians, vol. 89, no. 1, pp. 77–84, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. L. J. Stovner and C. Andrée, “Impact of headache in Europe: a review for the Eurolight project,” Journal of Headache and Pain, vol. 9, no. 3, pp. 139–146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. D. Solomon and K. L. Price, “Burden of migraine. A review of its socioeconomic impact,” PharmacoEconomics, vol. 11, no. 1, pp. 1–10, 1997. View at Google Scholar · View at Scopus
  9. F. M. Cutrer, “Pathophysiology of migraine,” Seminars in Neurology, vol. 30, no. 2, pp. 120–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Olesen, L. Friberg, T. S. Olsen et al., “Timing and topography of cerebral blood flow, aura, and headache during migraine attacks,” Annals of Neurology, vol. 28, no. 6, pp. 791–798, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Lauritzen, “Pathophysiology of the migraine aura. The spreading depression theory,” Brain, vol. 117, no. 1, pp. 199–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Ayata, “Cortical spreading depression triggers migraine attack: pro,” Headache, vol. 50, no. 4, pp. 725–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Olesen, R. Burstein, M. Ashina, and P. Tfelt-Hansen, “Origin of pain in migraine: evidence for peripheral sensitisation,” The Lancet Neurology, vol. 8, no. 7, pp. 679–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Levy, “Migraine pain and nociceptor activation—where do we stand?” Headache, vol. 50, no. 5, pp. 909–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Charles and S. M. Baca, “Cortical spreading depression and migraine,” Nature Reviews Neurology, vol. 9, no. 11, pp. 637–644, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Bolay, U. Reuter, A. K. Dunn, Z. Huang, D. A. Boas, and M. A. Moskowitz, “Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model,” Nature Medicine, vol. 8, no. 2, pp. 136–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Messlinger, U. Hanesch, M. Baumgartel, B. Trost, and R. F. Schmidt, “Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity,” Anatomy and Embryology, vol. 188, no. 3, pp. 219–237, 1993. View at Google Scholar · View at Scopus
  18. G. A. Lambert, L. Truong, and A. S. Zagami, “Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system,” Cephalalgia, vol. 31, no. 14, pp. 1439–1451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. J. Goadsby, A. R. Charbit, A. P. Andreou, S. Akerman, and P. R. Holland, “Neurobiology of migraine,” Neuroscience, vol. 161, no. 2, pp. 327–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Burstein, X. Zhang, D. Levy, K. R. Aoki, and M. F. Brin, “Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains,” Cephalalgia, vol. 34, no. 11, pp. 853–869, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. N. T. Mathew, “Pathophysiology of chronic migraine and mode of action of preventive medications,” Headache, vol. 51, no. 2, pp. 84–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. T. Mathew, J. Kailasam, and T. Seifert, “Clinical recognition of allodynia in migraine,” Neurology, vol. 63, no. 5, pp. 848–852, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Louter, J. E. Bosker, W. P. J. van Oosterhout et al., “Cutaneous allodynia as a predictor of migraine chronification,” Brain, vol. 136, no. 11, pp. 3489–3496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Aurora, A. Kulthia, and P. M. Barrodale, “Mechanism of chronic migraine,” Current Pain and Headache Reports, vol. 15, no. 1, pp. 57–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. K. Aurora, “Is chronic migraine one end of a spectrum of migraine or a separate entity?” Cephalalgia, vol. 29, no. 6, pp. 597–605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Aurora, “Spectrum of illness: understanding biological patterns and relationships in chronic migraine,” Neurology, vol. 72, supplement 5, pp. S8–S13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. K. Aurora, P. M. Barrodale, R. L. Tipton, and A. Khodavirdi, “Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies,” Headache, vol. 47, no. 7, pp. 996–1003, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H.-C. Diener, G. Bussone, H. de Liano et al., “Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks,” Cephalalgia, vol. 24, no. 11, pp. 947–954, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Lampl, M. Voelker, and H. C. Diener, “Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms,” Journal of Neurology, vol. 254, no. 6, pp. 705–712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. B. Lipton, J. S. Baggish, W. F. Stewart, J. R. Codispoti, and M. Fu, “Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study,” Archives of Internal Medicine, vol. 160, no. 22, pp. 3486–3492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Havanka-Kanniainen, “Treatment of acute migraine attack: ibuprofen and placebo compared,” Headache, vol. 29, no. 8, pp. 507–509, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. K. M. A. Welch, “Naproxen sodium in the treatment of migraine,” Cephalalgia, vol. 6, supplement 4, pp. 85–92, 1986. View at Google Scholar · View at Scopus
  33. The Diclofenac-K/Sumatriptan Migraine Study Group, “Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo,” Cephalalgia, vol. 19, no. 4, pp. 232–240, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Göbel, A. Heinze, U. Niederberger, T. Witt, and V. Zumbroich, “Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study,” Cephalalgia, vol. 24, no. 10, pp. 888–893, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. V. V. Myllylä, H. Havanka, L. Herrala et al., “Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study,” Headache, vol. 38, no. 3, pp. 201–207, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. R. B. Lipton, W. F. Stewart, R. E. Ryan Jr., J. Saper, S. Silberstein, and F. Sheftell, “Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain—three double-blind, randomized, placebo-controlled trials,” Archives of Neurology, vol. 55, no. 2, pp. 210–217, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. H.-C. Diener, V. Pfaffenrath, L. Pageler, H. Peil, and B. Aicher, “The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study,” Cephalalgia, vol. 25, no. 10, pp. 776–787, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Goldstein, S. D. Silberstein, J. R. Saper, R. E. Ryan Jr., and R. B. Lipton, “Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study,” Headache, vol. 46, no. 3, pp. 444–453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Kudrow, H. M. Thomas, G. Ruoff et al., “Valdecoxib for treatment of a single, acute, moderate to severe migraine headache,” Headache, vol. 45, no. 9, pp. 1151–1162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Evers, J. Áfra, A. Frese et al., “EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force,” European Journal of Neurology, vol. 16, no. 9, pp. 968–981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. L. M. Ross-Lee, M. J. Eadie, V. Heazlewood, F. Bochner, and J. H. Tyrer, “Aspirin pharmacokinetics in migraine. The effect of metoclopramide,” European Journal of Clinical Pharmacology, vol. 24, no. 6, pp. 777–785, 1983. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Waelkens, “Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study,” Cephalalgia, vol. 4, no. 2, pp. 85–90, 1984. View at Publisher · View at Google Scholar · View at Scopus
  43. E. A. Schulman and K. F. Dermott, “Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs,” Headache, vol. 43, no. 7, pp. 729–733, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. P. P. A. Humphrey, W. Feniuk, M. J. Perren, I. J. M. Beresford, M. Skingle, and E. T. Whalley, “Serotonin and migraine,” Annals of the New York Academy of Sciences, vol. 600, pp. 587–598, 1990. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Moskowitz and F. M. Cutrer, “Sumatriptan: a receptor-targeted treatment for migraine,” Annual Review of Medicine, vol. 44, pp. 145–154, 1993. View at Publisher · View at Google Scholar · View at Scopus
  46. P. J. Goadsby, “The pharmacology of headache,” Progress in Neurobiology, vol. 62, no. 5, pp. 509–525, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. M. D. Ferrari, K. I. Roon, R. B. Lipton, and P. J. Goadsby, “Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials,” The Lancet, vol. 358, no. 9294, pp. 1668–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. C. G. H. Dahlöf, D. Dodick, A. J. Dowson, and J. Pascual, “How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials,” Headache, vol. 42, no. 2, pp. 99–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. M. D. Ferrari, P. J. Goadsby, K. I. Roon, and R. B. Lipton, “Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials,” Cephalalgia, vol. 22, no. 8, pp. 633–658, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. The Subcutaneous Sumatriptan International Study Group, “Treatment of migraine attacks with sumatriptan,” The New England Journal of Medicine, vol. 325, no. 5, pp. 316–321, 1991. View at Publisher · View at Google Scholar · View at Scopus
  51. R. W. Evans and C. G. H. Dahlöf, “Determining triptan preference for the individual patient,” Headache, vol. 44, no. 7, pp. 723–725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. Z. Katsarava, G. Fritsche, M. Muessig, H. C. Diener, and V. Limmroth, “Clinical features of withdrawal headache following overuse of triptans and other headache drugs,” Neurology, vol. 57, no. 9, pp. 1694–1698, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. The Multinational Oral Sumatriptan Cafergot Comparative Study Group, “A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine,” European Neurology, vol. 31, no. 5, pp. 314–322, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. H.-C. Diener, J.-P. Jansen, A. Reches, J. Pascual, D. Pitei, and T. J. Steiner, “Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison,” European Neurology, vol. 47, no. 2, pp. 99–107, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. R. P. Shank, J. F. Gardocki, A. J. Streeter, and B. E. Maryanoff, “An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action,” Epilepsia, vol. 41, no. 1, pp. S3–S9, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Akerman and P. J. Goadsby, “Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura,” NeuroReport, vol. 16, no. 12, pp. 1383–1387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. K. R. Edwards, M. J. Glantz, J. A. Norton, and N. Cross, “Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients,” Cephalalgia, vol. 20, p. 316, 2000. View at Google Scholar
  58. J. R. Storey, C. S. Calder, D. E. Hart, and D. L. Potter, “Topiramate in migraine prevention: a double-blind, placebo-controlled study,” Headache, vol. 41, no. 10, pp. 968–975, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. J. L. Brandes, J. R. Saper, M. Diamond et al., “Topiramate for migraine prevention: a randomized controlled trial,” The Journal of the American Medical Association, vol. 291, no. 8, pp. 965–973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. S. D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs, “Topiramate in migraine prevention: results of a large controlled trial,” Archives of Neurology, vol. 61, no. 4, pp. 490–495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. National Clinical Guideline Centre, Headaches. Diagnosis and Management of Headaches in Young People and Adults (Full NICE Guideline), Clinical Guideline 150, National Institute for Health and Care Excellence, 2012, http://www.nice.org.uk/.
  62. M. Silvestrini, M. Bartolini, M. Coccia, R. Baruffaldi, R. Taffi, and L. Provinciali, “Topiramate in the treatment of chronic migraine,” Cephalalgia, vol. 23, no. 8, pp. 820–824, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. H.-C. Diener, G. Bussone, J. C. Van Oene, M. Lahaye, S. Schwalen, and P. J. Goadsby, “Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study,” Cephalalgia, vol. 27, no. 7, pp. 814–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Olesen, “The international classification of headache disorders, 2nd edition (ICHD-II),” Revue Neurologique, vol. 15, no. 6-7, pp. 689–691, 2005. View at Google Scholar
  65. S. D. Silberstein, R. B. Lipton, D. W. Dodick et al., “Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial,” Headache, vol. 47, no. 2, pp. 170–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. J. D. Gomersall and A. Stuart, “Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 36, no. 4, pp. 684–690, 1973. View at Publisher · View at Google Scholar · View at Scopus
  67. J. R. Couch and R. S. Hassanein, “Amitriptyline in migraine prophylaxis,” Archives of Neurology, vol. 36, no. 11, pp. 695–699, 1979. View at Publisher · View at Google Scholar · View at Scopus
  68. D. W. Dodick, F. Freitag, J. Banks et al., “Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs,” Clinical Therapeutics, vol. 31, no. 3, pp. 542–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Linde and K. Rossnagel, “Propranolol for migraine prophylaxis,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD003225, 2004. View at Google Scholar · View at Scopus
  70. D. K. Ziegler, A. Hurwitz, R. S. Hassanein, H. A. Kodanaz, S. H. Preskorn, and J. Mason, “Migraine prophylaxis. A comparison of propranolol and amitriptyline,” Archives of Neurology, vol. 44, no. 5, pp. 486–489, 1987. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Pradalier, G. Serratrice, M. Collard et al., “Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study,” Cephalalgia, vol. 9, no. 4, pp. 247–253, 1989. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Kangasniemi and C. Hedman, “Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study,” Cephalalgia, vol. 4, no. 2, pp. 91–98, 1984. View at Publisher · View at Google Scholar · View at Scopus
  73. J. E. Olsson, H. C. Behring, B. Forssman et al., “Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study,” Acta Neurologica Scandinavica, vol. 70, no. 3, pp. 160–168, 1984. View at Google Scholar
  74. T. J. Steiner, R. Joseph, C. Hedman, and F. C. Rose, “Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up,” Headache, vol. 28, no. 1, pp. 15–23, 1988. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Tfelt-Hansen, B. Standnes, P. Kangasneimi, H. Hakkarainen, and J. Olesen, “Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial,” Acta Neurologica Scandinavica, vol. 69, no. 1, pp. 1–8, 1984. View at Google Scholar · View at Scopus
  76. B. Olerud, C. L. Gustavsson, and B. Furberg, “Nadolol and propranolol in migraine management,” Headache, vol. 26, no. 10, pp. 490–493, 1986. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Worz, B. Reinhardt-Benmalek, K.-H. Grotemeyer, and M. Foh, “Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura—a randomized double-blind cross-over multicenter study,” Cephalalgia, vol. 11, no. 11, pp. 152–153, 1991. View at Google Scholar · View at Scopus
  78. V. Johannsson, L. R. Nilsson, T. Widelius et al., “Atenolol in migraine prophylaxis a double-blind cross-over multicentre study,” Headache, vol. 27, no. 7, pp. 372–374, 1987. View at Publisher · View at Google Scholar · View at Scopus
  79. F. M. Cutrer and M. A. Moskowitz, “The actions of valproate and neurosteroids in a model of trigeminal pain,” Headache, vol. 36, no. 10, pp. 579–585, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Hering and A. Kuritzky, “Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo,” Cephalalgia, vol. 12, no. 2, pp. 81–84, 1992. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Klapper, “Divalproex sodium in migraine prophylaxis: a dose-controlled study,” Cephalalgia, vol. 17, no. 2, pp. 103–108, 1997. View at Publisher · View at Google Scholar
  82. S. D. Silberstein, S. D. Collins, and H. Carlson, “Safety and efficacy of once-daily, extended-release divalproex sodium monotherapy for the prophylaxis of migraine headaches,” Cephalalgia, vol. 20, p. 269, 2000. View at Google Scholar
  83. F. G. Freitag, S. D. Collins, H. A. Carlson et al., “A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis,” Neurology, vol. 58, no. 11, pp. 1652–1659, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. R. G. Kaniecki, “A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura,” Archives of Neurology, vol. 54, no. 9, pp. 1141–1145, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. D. D. Mitsikostas and I. Polychronidis, “Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial,” Functional Neurology, vol. 12, no. 5, pp. 267–276, 1997. View at Google Scholar · View at Scopus
  86. M. Linde, W. M. Mulleners, E. P. Chronicle, and D. C. McCrory, “Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults,” Cochrane Database of Systematic Reviews, vol. 6, Article ID CD010611, 2013. View at Google Scholar · View at Scopus
  87. P. Louis, “A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine,” Headache, vol. 21, no. 6, pp. 235–239, 1981. View at Publisher · View at Google Scholar · View at Scopus
  88. F. G. Freitag, S. Diamond, and M. Diamond, “A placebo controlled trial of flunarizine in migraine prophylaxis,” Cephalalgia, vol. 11, supplement 11, pp. 157–158, 1991. View at Google Scholar · View at Scopus
  89. S. Diamond and F. G. Freitag, “A double blind trial of flunarizine in migraine prophylaxis,” Headache Quarterly, vol. 4, no. 2, pp. 169–172, 1993. View at Google Scholar · View at Scopus
  90. H. C. Diener, J. Matias-Guiu, E. Hartung et al., “Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily,” Cephalalgia, vol. 22, no. 3, pp. 209–221, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. C. H. Lucking, W. Oestreich, R. Schmidt, and D. Soyka, “Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients,” Cephalalgia, vol. 8, supplement 8, pp. 21–26, 1988. View at Google Scholar · View at Scopus
  92. N. Luo, W. Di, A. Zhang et al., “A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis,” Pain Medicine, vol. 13, no. 1, pp. 80–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Nappi, G. Sandrini, G. Savoini, A. Cavallini, C. de Rysky, and G. Micieli, “Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine,” Drugs, vol. 33, supplement 2, pp. 103–109, 1987. View at Publisher · View at Google Scholar · View at Scopus
  94. W.-D. Gerber, R. Schellenberg, M. Thom et al., “Cyclandelate versus propranolol in the prophylaxis of migraine—a double-blind placebo-controlled study,” Functional Neurology, vol. 10, no. 1, pp. 27–35, 1995. View at Google Scholar · View at Scopus
  95. H. C. Diener, M. Föh, C. Iaccarino et al., “Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol,” Cephalalgia, vol. 16, no. 6, pp. 441–447, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Siniatchkin, W.-D. Gerber, and A. Vein, “Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study,” Functional Neurology, vol. 13, no. 1, pp. 47–56, 1998. View at Google Scholar · View at Scopus
  97. H.-C. Diener, P. Krupp, T. Schmitt et al., “Cyclandelate in the prophylaxis of migraine: a placebo-controlled study,” Cephalalgia, vol. 21, no. 1, pp. 66–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Bostani, A. Rajabi, N. Moradian, N. Razazian, and M. Rezaei, “The effects of cinnarizine versus sodium valproate in migraine prophylaxis,” International Journal of Neuroscience, vol. 123, no. 7, pp. 487–493, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Rossi, G. Fiermonte, and F. Pierelli, “Cinnarizine in migraine prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness: an open-label pilot trial,” Functional Neurology, vol. 18, no. 3, pp. 155–159, 2003. View at Google Scholar · View at Scopus
  100. M. Togha, H. Ashrafian, and P. Tajik, “Open-label trial of cinnarizine in migraine prophylaxis,” Headache, vol. 46, no. 3, pp. 498–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. H. J. Gelmers, “Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine,” Headache, vol. 23, no. 3, pp. 106–109, 1983. View at Google Scholar · View at Scopus
  102. G. Bussone, S. Baldini, G. D'Andrea et al., “Nimodipine versus flunarizine in common migraine: a controlled pilot trial,” Headache, vol. 27, no. 2, pp. 76–79, 1987. View at Publisher · View at Google Scholar · View at Scopus
  103. H. Havanka-Kanniainen, E. Hokkanen, and V. V. Myllylä, “Efficacy of nimodipine in the prophylaxis of migraine,” Cephalalgia, vol. 5, no. 1, pp. 39–43, 1985. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Silberstein, S. Goode-Sellers, C. Twomey, J. Saiers, and J. Ascher, “Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis,” Cephalalgia, vol. 33, no. 2, pp. 101–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. T. J. Steiner, L. J. Findley, and A. W. C. Yuen, “Lamotrigine versus placebo in the prophylaxis of migraine with and without aura,” Cephalalgia, vol. 17, no. 2, pp. 109–112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Silberstein, J. Saper, F. Berenson, M. Somogyi, K. McCague, and J. D'Souza, “Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study,” Neurology, vol. 70, no. 7, pp. 548–555, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Tronvik, L. J. Stovner, G. Helde, T. Sand, and G. Bovim, “Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial,” The Journal of the American Medical Association, vol. 289, no. 1, pp. 65–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. L. J. Stovner, M. Linde, G. B. Gravdahl et al., “A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study,” Cephalalgia, vol. 34, no. 7, pp. 523–532, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. H. Schrader, L. J. Stovner, G. Helde, T. Sand, and G. Bovim, “Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study,” British Medical Journal, vol. 322, no. 7277, pp. 19–22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Adly, J. Straumanis, and A. Chesson, “Fluoxetine prophylaxis of migraine,” Headache, vol. 32, no. 2, pp. 101–104, 1992. View at Publisher · View at Google Scholar · View at Scopus
  111. J. R. Saper, S. D. Silberstein, A. E. Lake III, and M. E. Winters, “Double-blind trial of fluoxetine: chronic daily headache and migraine,” Headache, vol. 34, no. 9, pp. 497–502, 1994. View at Publisher · View at Google Scholar · View at Scopus
  112. S. N. Ozyalcin, G. K. Talu, E. Kiziltan, B. Yucel, M. Ertas, and R. Disci, “The efficacy and safety of venlafaxine in the prophylaxis of migraine,” Headache, vol. 45, no. 2, pp. 144–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Bulut, M. S. Berilgen, A. Baran, A. Tekatas, M. Atmaca, and B. Mungen, “Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study,” Clinical Neurology and Neurosurgery, vol. 107, no. 1, pp. 44–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. J. D. Carroll and W. P. Maclay, “Pizotifen (BC 105) in migraine prophylaxis,” Current Medical Research and Opinion, vol. 3, no. 2, pp. 68–71, 1975. View at Publisher · View at Google Scholar · View at Scopus
  115. P. Kangasniemi, “Placebo, 1-isopropylnoradrenochrome 5 monosemicarbazone and pizotifen in migraine prophylaxis,” Headache, vol. 19, no. 4, pp. 219–222, 1979. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Hübbe, “The prophylactic treatment of migraine with an antiserotonin pizotifen,” Acta Neurologica Scandinavica, vol. 49, no. 1, pp. 108–114, 1973. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Gawel, “A double-blind, cross-over study of nimodipine versus pizotyline in common and classical migraine,” Cephalalgia, vol. 7, supplement 6, pp. 453–454, 1987. View at Google Scholar
  118. P. O. Osterman, “A comparison between placebo, pizotifen and 1 isopropyl 3 hydroxy 5 semicarbazono 6 oxo 2.3.5.6 tetrahydroindol (Divascan) in migraine prophylaxis,” Acta Neurologica Scandinavica, vol. 56, no. 1, pp. 17–28, 1977. View at Google Scholar · View at Scopus
  119. R. N. Gray, R. E. Goslin, D. C. McCrory, K. Eberlein, J. Tulsky, and V. Hasselblad, “Drug treatments for the prevention of migraine headache,” Technical Review 2.3, 1999, (Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025. Available from the National Technical Information Service; NTIS Accession No. 127953.). View at Google Scholar
  120. B. Kåss and K. Nestvold, “Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine: a comparative trial,” Acta Neurologica Scandinavica, vol. 61, no. 6, pp. 351–356, 1980. View at Google Scholar · View at Scopus
  121. P. Louis, J. Schoenen, and C. Hedman, “Metoprolol v. clonidine in the prophylactic treatment of migraine,” Cephalalgia, vol. 5, no. 3, pp. 159–165, 1985. View at Publisher · View at Google Scholar · View at Scopus
  122. U. Danesch and R. Rittinghausen, “Safety of a patented special butterbur root extract for migraine prevention,” Headache, vol. 43, no. 1, pp. 76–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. R. B. Lipton, H. Göbel, K. M. Einhäupl, K. Wilks, and A. Mauskop, “Petasites hybridus root (butterbur) is an effective preventive treatment for migraine,” Neurology, vol. 63, no. 12, pp. 2240–2244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. H. C. Diener, V. W. Rahlfs, and U. Danesch, “The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy riteria,” European Neurology, vol. 51, no. 2, pp. 89–97, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. M. H. Pittler and E. Ernst, “Feverfew for preventing migraine,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD002286, 2004. View at Google Scholar · View at Scopus
  126. J. Schoenen, J. Jacquy, and M. Lenaerts, “Effectiveness of high-dose riboflavin in migraine prophylaxis. a randomized controlled trial,” Neurology, vol. 50, no. 2, pp. 466–470, 1998. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Peikert, C. Wilimzig, and R. Köhne-Volland, “Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study,” Cephalalgia, vol. 16, no. 4, pp. 257–263, 1996. View at Publisher · View at Google Scholar · View at Scopus
  128. V. Pfaffenrath, P. Wessely, C. Meyer et al., “Magnesium in the prophylaxis of migraine—a double-blind, placebo-controlled study,” Cephalalgia, vol. 16, no. 6, pp. 436–440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  129. F. Facchinetti, G. Sances, P. Borella, A. R. Genazzani, and G. Nappi, “Magnesium prophylaxis of menstrual migraine: effects of intracellular magnesium,” Headache, vol. 31, no. 5, pp. 298–301, 1991. View at Publisher · View at Google Scholar · View at Scopus
  130. R. Gooriah and F. Ahmed, “Therapeutic uses of botulinum toxin,” Journal of Clinical Toxicology, vol. 5, article 225, 2015. View at Publisher · View at Google Scholar
  131. W. J. Binder, M. F. Brin, A. Blitzer, L. D. Schoenrock, and J. M. Pogoda, “Botulinum toxin type a (BOTOX) for treatment of migraine headaches: an open-label study,” Otolaryngology—Head and Neck Surgery, vol. 123, no. 6, pp. 669–676, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. F. G. Freitag, S. Diamond, M. Diamond, and G. Urban, “Botulinum toxin type A in the treatment of chronic migraine without medication overuse,” Headache, vol. 48, no. 2, pp. 201–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. S. K. Aurora, D. W. Dodick, C. C. Turkel et al., “OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial,” Cephalalgia, vol. 30, no. 7, pp. 793–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. H. C. Diener, D. W. Dodick, S. K. Aurora et al., “OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial,” Cephalalgia, vol. 30, no. 7, pp. 804–814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. D. W. Dodick, C. C. Turkel, R. E. DeGryse et al., “OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program,” Headache, vol. 50, no. 6, pp. 921–936, 2010. View at Publisher · View at Google Scholar
  136. F. Ahmed and R. Gooriah, “OnabotulinumtoxinA for chronic migraine: a critical appraisal,” Therapeutics and Clinical Risk Management, vol. 11, pp. 1003–1013, 2015. View at Publisher · View at Google Scholar
  137. A. Ashkenazi and M. Levin, “Greater occipital nerve block for migraine and other headaches: is it useful?” Current Pain and Headache Reports, vol. 11, no. 3, pp. 231–235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. W. B. Young, “Blocking the greater occipital nerve: utility in headache management,” Current Pain and Headache Reports, vol. 14, no. 5, pp. 404–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. S. K. Afridi, K. G. Shields, R. Bhola, and P. J. Goadsby, “Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection,” Pain, vol. 122, no. 1-2, pp. 126–129, 2006. View at Publisher · View at Google Scholar
  140. M. J. Gawel and P. J. Rothbart, “Occipital nerve block in the management of headache and cervical pain,” Cephalalgia, vol. 12, no. 1, pp. 9–13, 1992. View at Publisher · View at Google Scholar · View at Scopus
  141. F. Ceccherelli, F. Ambrosio, M. Avila, G. Duse, A. Munari, and G. P. Giron, “Acupuncture vs. placebo in the common migraine: a double-blind study,” Cephalalgia, vol. 7, supplement 6, pp. 499–500, 1987. View at Google Scholar
  142. G. Allais, C. De Lorenzo, P. E. Quirico et al., “Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine,” Headache, vol. 42, no. 9, pp. 855–861, 2002. View at Publisher · View at Google Scholar · View at Scopus
  143. M. A. Linde, J. Y. Carlsson, and C. G. H. Dahlöf, “Impact of acupuncture as add-on therapy to pharmacological treatment of migraine: a pilot study,” Pain Clinic, vol. 12, no. 3, pp. 247–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Alecrim-Andrade, J. A. Maciel-Júnior, X. Carne i Cladellas, H. R. Correa-Filho, H. C. Machado, and G. M. S. Vasconcelos, “Efficacy of acupuncture in migraine attack prophylaxis: a randomized sham-controlled trial,” Cephalalgia, vol. 25, no. 10, article 942, 2005. View at Google Scholar
  145. K. Linde, A. Streng, S. Jürgens et al., “Acupuncture for patients with migraine: a randomized controlled trial,” The Journal of the American Medical Association, vol. 293, no. 17, pp. 2118–2125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. H.-C. Diener, K. Kronfeld, G. Boewing et al., “Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial,” The Lancet Neurology, vol. 5, no. 4, pp. 310–316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  147. E. Facco, A. Liguori, F. Petti et al., “Traditional acupuncture in migraine: a controlled, randomized study,” Headache, vol. 48, no. 3, pp. 398–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Streng, K. Linde, A. Hoppe et al., “Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis,” Headache, vol. 46, no. 10, pp. 1492–1502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Hróbjartsson and P. C. Gøtzsche, “Placebo interventions for all clinical conditions,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003974, 2010. View at Google Scholar · View at Scopus
  150. K. Linde, K. Niemann, and K. Meissner, “Are sham acupuncture interventions more effective than (other) placebos? A re-analysis of data from the cochrane review on placebo effects,” Forschende Komplementarmedizin, vol. 17, no. 5, pp. 259–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. H. H. Moffet, “Sham acupuncture may be as efficacious as true acupuncture: a systematic review of clinical trials,” Journal of Alternative and Complementary Medicine, vol. 15, no. 3, pp. 213–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Linde, G. Allais, B. Brinkhaus, E. Manheimer, A. Vickers, and A. R. White, “Acupuncture for migraine prophylaxis,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001218, 2009. View at Google Scholar · View at Scopus
  153. R. Hassanzadeh, J. C. Jones, and E. L. Ross, “Neuromodulation for intractable headaches,” Current Pain and Headache Reports, vol. 18, article 392, 2014. View at Publisher · View at Google Scholar · View at Scopus
  154. B. M. Clarke, A. R. M. Upton, M. V. Kamath, T. Al-Harbi, and C. M. Castellanos, “Transcranial magnetic stimulation for migraine: clinical effects,” Journal of Headache and Pain, vol. 7, no. 5, pp. 341–346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. T. M. Mohammad, G. Hughes, and M. Nkrumah, “Self-administered transcranial magnetic stimulation (TMS) during the aura phase improved and aborts headache,” Headache, vol. 46, p. 857, 2006. View at Google Scholar
  156. R. B. Lipton, D. W. Dodick, S. D. Silberstein et al., “Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial,” The Lancet Neurology, vol. 9, no. 4, pp. 373–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  157. F. Brighina, A. Piazza, G. Vitello et al., “rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study,” Journal of the Neurological Sciences, vol. 227, no. 1, pp. 67–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  158. M. Teepker, J. Hötzel, N. Timmesfeld et al., “Low-frequency rTMS of the vertex in the prophylactic treatment of migraine,” Cephalalgia, vol. 30, no. 2, pp. 137–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. U. K. Misra, J. Kalita, and S. K. Bhoi, “High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study,” Journal of Neurology, vol. 260, no. 11, pp. 2793–2801, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. R. B. Lipton and S. H. Pearlman, “Transcranial magnetic simulation in the treatment of migraine,” Neurotherapeutics, vol. 7, no. 2, pp. 204–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. http://www.eneura.com/.
  162. D. W. Dodick, “Occipital nerve stimulation for chronic cluster headache,” Advanced Studies in Medicine, vol. 3, no. 6, pp. S569–S571, 2003. View at Google Scholar · View at Scopus
  163. C. A. Popeney and K. M. Aló, “Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine,” Headache, vol. 43, no. 4, pp. 369–375, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. M. S. Matharu, T. Bartsch, N. Ward, R. S. J. Frackowiak, R. Weiner, and P. J. Goadsby, “Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study,” Brain, vol. 127, no. 1, pp. 220–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. J. R. Saper, D. W. Dodick, S. D. Silberstein, S. McCarville, M. Sun, and P. J. Goadsby, “Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study,” Cephalalgia, vol. 31, no. 3, pp. 271–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. S. D. Silberstein, D. W. Dodick, J. Saper et al., “Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study,” Cephalalgia, vol. 32, no. 16, pp. 1165–1179, 2012. View at Publisher · View at Google Scholar
  167. G. Serra and F. Marchioretto, “Occipital nerve stimulation for chronic migraine: a randomized trial,” Pain Physician, vol. 15, no. 3, pp. 245–253, 2012. View at Google Scholar · View at Scopus
  168. R. Lipton, P. Goadsby, R. Cady et al., “PRISM study: occipital nerve stimulation for treatment-refractory migraine,” Cephalalgia, vol. 29, pp. 1–166, 2009, abstract P047. View at Google Scholar
  169. S. N. Narouze and L. Kapural, “Supraorbital nerve electric stimulation for the treatment of intractable chronic cluster headache: a case report,” Headache, vol. 47, no. 7, pp. 1100–1102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Hann and A. Sharan, “Dual occipital and supraorbital nerve stimulation for chronic migraine: a single-center experience, review of literature, and surgical considerations,” Neurosurgical Focus, vol. 35, no. 3, article E9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  171. K. L. Reed, S. B. Black, C. J. Banta II, and K. R. Will, “Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience,” Cephalalgia, vol. 30, no. 3, pp. 260–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. E. A. Schulman, A. E. Lake III, P. J. Goadsby et al., “Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society,” Headache, vol. 48, no. 6, pp. 778–782, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. J. Schoenen, B. Vandersmissen, S. Jeangette et al., “Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial,” Neurology, vol. 80, no. 8, pp. 697–704, 2013. View at Publisher · View at Google Scholar
  174. D. Magis, S. Sava, T. S. d'Elia, R. Baschi, and J. Schoenen, “Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population,” The Journal of Headache and Pain, vol. 14, article 95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. Cefaly, http://www.cefaly.co.uk/.